0
I Use This!
Very Low Activity
Analyzed about 17 hours ago. based on code collected about 21 hours ago.

Project Summary

Miew is a high performance web tool for advanced visualization and manipulation of molecular structures.

Miew provides a full-featured set of tools for 3D visualization and editing of small molecules as well as large molecular complexes, including means to view, analyze, and modify the 3D structure of a molecule. It works as a standalone HTML5 web application or integrates as a component into your web pages. The latest versions of WebGL-enabled desktop (Chrome, Firefox, Safari, Opera, Edge, IE11) and mobile (iOS, Android) browsers are supported.

Tags

3d bioinformatics cheminformatics chemistry dna javascript molecular_science protein visualization webgl

In a Nutshell, Miew - 3D Molecular Viewer...

Quick Reference

MIT License
Permitted

Commercial Use

Modify

Distribute

Sub-License

Private Use

Forbidden

Hold Liable

Required

Include Copyright

Include License

These details are provided for information only. No information here is legal advice and should not be used as such.

Project Security

Vulnerabilities per Version ( last 10 releases )

There are no reported vulnerabilities

Project Vulnerability Report

Security Confidence Index

Poor security track-record
Favorable security track-record

Vulnerability Exposure Index

Many reported vulnerabilities
Few reported vulnerabilities

Did You Know...

  • ...
    nearly 1 in 3 companies have no process for identifying, tracking, or remediating known open source vulnerabilities
  • ...
    you can embed statistics from Open Hub on your site
  • ...
    65% of companies leverage OSS to speed application development in 2016
  • ...
    search using multiple tags to find exactly what you need
About Project Security

Languages

JavaScript
62%
HTML
29%
TypeScript
6%
4 Other
3%

30 Day Summary

Mar 26 2024 — Apr 25 2024

12 Month Summary

Apr 25 2023 — Apr 25 2024
  • 8 Commits
    Down -1 (11%) from previous 12 months
  • 4 Contributors
    Up + 3 (300%) from previous 12 months